Latest News and Press Releases

Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide, announced today its participation in the Jefferies...

Advanz Pharma secures exclusive rights from Alvotech to commercialize three biosimilar candidates in Europe in addition to previously partnered programsThe agreement includes proposed biosimilars to...

Samningurinn felur í sér greiðslu við undirritun og áfangagreiðslur, samtals að upphæð allt að 23,1 milljarður króna (160 milljónir evra), en að auki munu samstarfsaðilarnir skipta með sér tekjum af...

Advanz Pharma secures exclusive rights from Alvotech to commercialize three biosimilar candidates in Europe in addition to previously partnered programsThe agreement includes proposed biosimilars to...

Aðalfundur Alvotech verður haldinn miðvikudaginn 25. júní 2025, kl. 09.00 CEST á skrifstofu Arendt & Medernach að 41A Avenue John F. Kennedy, L-1855 Lúxemborg. Dagskrá fundarins er að finna í...

The Annual General Meeting of Alvotech will be held on Wednesday June 25, 2025, at 09.00 a.m. CEST at the premises of Arendt & Medernach at 41A, Avenue John F. Kennedy L-1855 Luxembourg, Grand...

Í viðhengi er tilkynning um viðskipti stjórnenda og tengdra aðila sem lögð var inn til birtingar hjá fjármálaeftirliti Lúxemborgar, Luxembourg Commission de Surveillance du Secteur Financier (CSSF),...

Attached is a copy of a filing with the Luxembourg Commission de Surveillance du Secteur Financier (CSSF) regarding transactions of managers and closely associated persons, announcing the acquisition...

Alvotech (NASDAQ: ALVO) tilkynnti í dag að fyrirtækið hefði gengið frá samningi við DNB Carnegie Investment Bank AB (“DNB Carnegie”) um viðskiptavakt með bréf félagsins á Nasdaq markaðnum í...

REYKJAVIK, ICELAND AND STOCKHOLM, SWEDEN (May 19, 2025) — Alvotech (NASDAQ: ALVO, the “Company”) has entered into agreement with DNB Carnegie Investment Bank AB (publ) (“DNB Carnegie”) regarding...